News

Categories

August 25, 2026

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

August 11, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

August 6, 2026

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

July 16, 2026

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

June 29, 2026

Zymeworks to Acquire Theravance Biopharma, Inc.

May 14, 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

May 13, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

May 7, 2026

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

April 21, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

April 17, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

April 16, 2026

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

April 9, 2026

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth